Octopharma

IFBC has been mandated by Octapharma to prepare a valuation in the context of STAF to the attention of the Swiss tax authorities. The valuation of Octapharma has been based on the DCF approach and considers tax-specific circumstances. The resulting value was benchmarked using multiples of comparable companies and transactions. Octapharma Group is specialized in the development and production of preparations from human plasma. The group focuses on highly pure, virus-inactivated drugs for the treatment of diseases in the fields of hematology, immunology and intensive care medicine.